whatshot

MYOV   $26.98  0.0 Market Closed

Myovant Sciences Ltd
show_chart Advanced Chart of MYOV
Last Events:

2023-03-29 Trend pattern changed from восходящий треугольник to симметричный треугольник.

2023-03-29 Signal in Stochastic changed from bullish to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: signal line crossed the middle level.

2023-03-29 Signal in EMA100 changed from n/a to bullish reversal. 2022-07-27 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.

2023-03-29 Trend changed from linear up to flat and up.

2023-03-29 Trend pattern changed from симметричный треугольник to восходящий треугольник.

2023-03-29 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: signal line crossed the middle level.

2023-03-29 Signal in EMA100 changed from bullish reversal to n/a. 2022-07-27 the price crossed up the moving average line and getting closer to the MA, which means that the upside trend weakens.

2023-03-29 Trend changed from flat and up to linear up.

Current temperature: 0.00
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 21.77
Target: 27.00
High with 50% probability: 32.21
Analyst Recommendations:
Number of estimates 3
Target Price Mean 27.00
Mean unverified/preliminary 27.00 / 27.00
Target Price Low / High 27.00 / 27.00
Median / STD DEV 27.00 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy Buy -
rsi ActivelyBuy ActivelyBuy -
macd - - -
stoch - - -
ma20 ActivelyBuy ActivelyBuy -
ma50 - - -
ma100 ActivelyBuy Buy -
Candlestick PatternMarch 9, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN BMG637AM1024
ceo Mr. David C. Marek
Website https://myovant.com
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.